Journal article
Psychotropic Medication Use and Postmenopausal Breast Cancer Risk
Cancer epidemiology, biomarkers & prevention, Vol.29(1), pp.254-256
01/2020
DOI: 10.1158/1055-9965.EPI-19-0776
PMCID: PMC6954318
PMID: 31685559
Abstract
Prior studies evaluating psychotropic medications in relation to breast cancer risk are inconsistent and have not separately evaluated invasive and
disease.
We estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association of psychotropic medication use (any, typical antipsychotics, atypical antipsychotics, and lithium) with invasive and
breast cancer risk among Women's Health Initiative participants (
= 155,737).
Prevalence of psychotropic medication use was low (
= 642; 0.4%). During an average 14.8 (SD, 6.5) years of follow-up, 10,067 invasive and 2,285
breast tissues were diagnosed. Any psychotropic medication use was not associated with invasive breast cancer risk compared with nonusers (HR, 0.82; 95% CI, 0.57-1.18).
breast cancer risk was higher among "typical" antipsychotic medication users compared with nonusers (HR, 2.05; 95% CI, 0.97-4.30).
These findings do not support an association of psychotropic medication use with invasive breast cancer risk. The possible elevation in
breast cancer risk associated with "typical" antipsychotics could not be explained by differences in screening mammography utilization and merits further study.
Our findings contribute to knowledge of the safety profile of psychotropic medications and may be useful to clinicians and patients considering use of these medications.
Details
- Title: Subtitle
- Psychotropic Medication Use and Postmenopausal Breast Cancer Risk
- Creators
- Anna George - University of Massachusetts AmherstSusan R Sturgeon - University of Massachusetts AmherstSusan E Hankinson - University of Massachusetts AmherstAladdin H Shadyab - University of California San DiegoRobert B Wallace - University of IowaKatherine W Reeves - University of Massachusetts Amherst
- Resource Type
- Journal article
- Publication Details
- Cancer epidemiology, biomarkers & prevention, Vol.29(1), pp.254-256
- DOI
- 10.1158/1055-9965.EPI-19-0776
- PMID
- 31685559
- PMCID
- PMC6954318
- NLM abbreviation
- Cancer Epidemiol Biomarkers Prev
- ISSN
- 1055-9965
- eISSN
- 1538-7755
- Grant note
- HHSN268201600018C / NHLBI NIH HHS P30 ES005605 / NIEHS NIH HHS HHSN268201600003C / NHLBI NIH HHS HHSN268201600004C / NHLBI NIH HHS HHSN268201600002C / NHLBI NIH HHS HHSN268201600001C / NHLBI NIH HHS
- Language
- English
- Date published
- 01/2020
- Academic Unit
- Epidemiology; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984363597002771
Metrics
15 Record Views